Abstract: The invention provides a hydrosol of a pharmacological active agent in an intravenous applicable, stabilised, pharmaceutically acceptable form, which form is suspended or is dry and re-suspendable in an aqueous medium.The hydrosol contains solid active agent particles, e.g. of dihydropyridines or cyclosporines.

Abstract: The present invention provides a pharmaceutical composition for the transdermal systemic administration of an active agent characterized in that the active agent is bopindolol or methysergide. Also the present invention provides a pharmaceutical composition for the transdermal systemic administration of a pharmacologically active agent characterized in that it contains bopindolol, tizanidine, clemastine, ketotifen or methysergide as active agent in a reservoir comprising a hydrophilic polymer. Furthermore a pharmaceutical composition for the transdermal systemic administration of pharmacologically active agents characterised in that the pharmacologically active agent is in a reservoir comprising a polyacrylate polymer containing cationic ester groups.

Abstract: An inhaler for delivering metered doses of a particulate drug. The inhaler is formed of a housing, a drug reservoir attached to the housing to contain multiple doses of the particulate drug, a drug transporting slide in the housing that contains a metering chamber of volume corresponding to a desired dose of the drug, and a vacuum pump that creates a partial vacuum in the metering chamber. The drug transporting slide is movable from a load position, in which it communicates with the drug reservoir to receive in its metering chamber drug from the drug reservoir, to a release position in which it communicates with an air outlet passage to release drug from the metering chamber into the air outlet passage. The drug reservoir has an air permeable portion that permits air flow into the drug reservoir but prevents drug escape. In use, the vacuum pump draws a dose of drug into the metering chamber. The drug transporting slide then moves to deposit the drug in the outlet passage for inhalation.

Abstract: Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.

Abstract: Retaining device for patient feeding set to prevent unintentional disconnect of the feeding solution supply tube from the feeding tube.

Abstract: Method for placing a guide wire through a gastrostomy tube which has a plug through which only the guide wire can pass in slidable communication. The plug prevents air from escaping from the stomach, thus, preventing the collapse of the stomach during the guide wire placement. The plug may comprise a substantially cylindrical member having a longitudinal bore for receiving the guide wire in slidable communication.

Abstract: A nutritionally complete feeding composition contains soluble fiber, especially hydrolyzed guar gum or pectin. This composition provides nourishment to colon cells, preventing bacterial sepsis and also preventing diarrhea.

Abstract: Nutritional supplements and methods of use of the supplements to maximally stimulate gallbladder contraction in patients undergoing rapid weight loss, to prevent the build up of bilary sludge and/or gallstones.

Abstract: The invention provides immunostimulatory compositions comprising an aggregate immunostimulatory amount ofa) a compound associated with the synthesis of polyamines,b) a nucleobase source,c) omega-3 polyunsaturated fatty acids, andd) omega-6 polyunsaturated fatty acidsthe use of such compositions and their manufacture.

Abstract: A closure device for connection to a fluid container which has an opening for receiving the device. The closure device has a base section which may sealably cover the container opening. The base section has a spike receiving opening passing there through with at least one air vent on the base section which is spaced from the spike receiving opening. A hydrophobic air filter, is associated with the air vent. Adjoining the base section is an internal cover, which lies over the aperture, covering it and the base section. The internal cover has a pierceable portion which is in alignment with the spike receiving opening of the base section.

Abstract: Polymyxin B carrier conjugates, especially polymyxin B-dextran, are water soluble, have a greater half-life in the bloodstream and are significantly less toxic than native polymyxin B.

Abstract: A nasal pharmaceutical composition incorporates a non-toxic agent which is capable of increasing the ciliary function e.g. caffeine and at least partially antagonizing the ciliary function depressant effect of the active agent e.g. dihydroergotamine or any other constituent present in the composition.

Abstract: Novel monoclonal antibodies capable of distinguishing between cyclosporins, e.g. Cyclosporine, and metabolites, e.g. Cyclosporins 17 and 18, are produced, e.g. starting from novel cyclosporins having an activated coupling group, e.g. activated carboxy group, e.g. (i) [(O-succinimidooxysuccinyl)-Thr].sup.2 -Cyclosporine and (ii) [(N-.epsilon.-succinimidooxysuccinyl)-(D)Lys].sup.8 -Cyclosporine. Cyclosporin starting materials required for the production of cyclosporins of type (ii), e.g. [(D)Lys].sup.8 -Cyclosporine are also new and additionally have utility in the preparation of novel labelled cyclosporin derivatives, as well as antibodies and antisera generally. Also claimed are novel antigenic conjugates and hybridoma cell lines used in the production of antibodies and antisera as aforesaid as well as assay kits comprising novel antisera, antibodies and/or labelled cyclosporins as aforesaid.

Abstract: Suppositories comprising a suppository base, a calcitonin and taurocholic acid or a pharmaceutically acceptable salt thereof exhibit improved bioavailability and are well tolerated.

Abstract: Compositions having improved anti-plaque activity comprise a synergistic combination of a) a morpholinoamino alcohol, such as 3-(4-propylheptyl)-4-(2-hydroxyethyl) morpholine, and b) a chelating agent such as ethylenediaminetetraacetic acid.

Abstract: A sterile bandage suitable for external application to a wound or injury of the human skin comprising a backing layer, a non-toxic pigmented composition coated onto or embedded into the top side of said backing layer, wherein said pigmented composition comprises one or more pigments having a melanin likeness in appearance so as to substantially match the appearance of said human skin.

Abstract: The invention provides an anti-bacterial oral composition such as mouthrinse which includes a bis-biguanido hexane compound such as chlorhexidine and compounds thereof, certain non-ionic surfactants which are poly(oxyethylene)-poly(oxypropylene) block copolymers having an HLB of between 10 and 30 or an ethoxylated hydrogenated caster oil containing from about 10 to 200 moles of added ethylene oxide and sorbitol in high concentrations. The oral composition is found to increase the activity of the bis-biguanido compound from 25% to 150%.

Abstract: Compositions having improved anti-plaque and anti-gingivitis activity comprise a synergistic combination of a) a morpholinoamino alcohol or salt thereof, such as 3-(4- propylheptyl)-4-(2-hydroxyethyl) morpholine, and b) a metal salt, such as the salts of divalent zinc, copper and magnesium.

Abstract: Compositions having improved anti-plaque and anti-gingivitis activity comprises a synergistic combination of a) a morpholinoamino alcohol, such as 3-(4-propylheptyl)-4-(2-hydroxyethyl)morpholine and b) and antibiotic, such as the aminoglycosides, amphenicols, ansamycins, carbapenems, cephalosporins, cephamycins, monobactams, oxacephems, penicillins, lincosamides, macrolides, polypeptides and tetracyclines.